ZIOPHARM Oncology Stock Price (NASDAQ:ZIOP)

Add to My Stocks
$6.1 $0.11 (1.77%) ZIOP stock closing price Feb 24, 2017 (Closing)
YOUR DAILY UPDATE ON
ZIOP
ZIOPHARM Oncology
24 FEB 2017
amigobulls logo
ZIOP hand_up
ZIOP vs S&P 500
Closing Price: Feb 24, 2017
ZIOP
$6.1 ( -1.77%)
S&P 500
2367.3 ( 0.15%)
ZIOP
52 Week Price Range
1 Year Return: -18.18%
Q4 Growth*
Poor
Profitable ?
No
net image
2016 Q4 Net Loss
-2406%
home image
Rating
ZIOP POOR
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen
0:00
/

ZIOPHARM Oncology Snapshot Video

11 5 2

ZIOP Stock Details

Prev Close* : $6.21
Market Cap:
$807.5M
Day Low: $6.05
52 Week Low: $4.45
Open: $6.18
Volume: 1586056
Day High: $6.31
52 Week High: $9.74
Dividend:
N/A

Latest Stock Market News

Latest Articles

ZIOPHARM Oncology News - From Partners

ZIOP Stockcharts

View ZIOP PE ratio, PS ratio stocks charts and compare with peers.
ZIOP Chart
Note: Compare ZIOPHARM Oncology stock price history with the index and industry peers.

ZIOPHARM Oncology Valuation

PS ratio (
price to sales ratio
)
115.89

ZIOPHARM Oncology Financial Ratios

Asset Turnover
0.05
Receivables Turnover
19.02

ZIOP Industry Peers

Company Price Change (%)
Basilea Pharma (BPMUF)84.453.9 (4.84%)
Amicus Therapeutics (FOLD)5.960.09 (1.49%)
Nantkwest (NK)4.550.17 (3.6%)
Juno Therapeutics (JUNO)21.440.68 (3.07%)
Kite Pharma (KITE)52.60.37 (0.7%)
Incyte (INCY)131.219.26 (7.59%)
Celgene (CELG)118.231.23 (1.03%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
Incyte (INCY)131.219.26 (7.59%)
Sarepta Therapeutics (SRPT)32.021.87 (6.2%)
Stemline Therapeutics (STML)6.850.4 (6.2%)
Bluebird Bio (BLUE)823.7 (4.73%)
Puma Biotech (PBYI)36.21.5 (4.32%)
Sangamo BioSciences (SGMO)40.15 (3.9%)
Epizyme (EPZM)12.150.45 (3.85%)
Top gainers from Medical-Biomed-Genetics industry
* As of Feb 25, 2017
CompanyPriceChange (%)
Achillion Pharma (ACHN)3.860.38 (8.96%)
Chromadex (CDXC)2.740.13 (4.53%)
Idera Pharma (IDRA)1.670.06 (3.47%)
Inovio Pharma (INO)6.680.22 (3.19%)
VIVUS (VVUS)1.140.03 (2.56%)
Ligand Pharma (LGND)100.382.46 (2.39%)
Compugen (CGEN)4.30.1 (2.27%)
Top losers from Medical-Biomed-Genetics industry
* As of Feb 25, 2017

ZIOPHARM Oncology Financial Statements

income statement20152014201320122011
Net Sales Or Revenues4.33M1.37M0.8M0.8M0.66M
Net Income-120.08M-31.78M-57.1M-96.13M-63.77M
Total Operating Expense124.42M44.86M58.51M102.96M72.06M
view ZIOPHARM Oncology Inc. income statement
balance sheet20152014201320122011
Total Assets153.72M45.23M71.75M83.4M108.1M
Total Liabilities66.35M11.39M22.37M34.95M36.5M
Shareholders Equity87.37M33.84M49.38M48.44M71.6M
view ZIOPHARM Oncology Inc. balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities44.43M1.64M-6.04M-0.93M12.04M
Net Cash From (Used By) Operating Activities-0.01M-36.65M-59.5M-78.83M-38.83M
Increase (Decrease) In Prop Plant And Equipment-0.41M-0.19M-0.13M-1.55M-1.15M
view ZIOPHARM Oncology Inc. cashflow statement

ZIOPHARM Oncology Inc. Stock News - Partner Headlines

ZIOPHARM Oncology Stock Message Board

ZIOPHARM Oncology stock lost -1.77 %, and the last close price as of 24 Feb, 2017 is 6.1 for ZIOP stock. The total market value as denoted by 822.06M for ZIOPHARM Oncology, is the market value of the company's outstanding shares. ZIOPHARM Oncology valuation can be guaged using various valuation metrics like the price to earnings ratio.

Demand for a stock decides its stock market price. For example, if more investors want to buy ZIOP stock than sell it, then ZIOPHARM Oncology stock price goes up. Conversely, if more investors wanted to sell ZIOP stock than buy it, there would be greater supply than demand, and the stock price would fall. 1586056 shares were traded with a closing stock price of 6.1 as of 24 Feb, 2017, as can be seen from ZIOPHARM Oncology stock quote. One can view ZIOPHARM Oncology stock chart to follow the stock price trend. The board of directors decide what percentage of a company's earnings will be paid out as dividends. ZIOPHARM Oncology stock price history, gives the entire historical data for ZIOP stock.